Phase III melanoma combo data lift Array

Array BioPharma Inc. (NASDAQ:ARRY) jumped $2.96 (81%) to $6.61 on Monday after it and partner Laboratoires Pierre Fabre S.A. (Castres, France) said encorafenib ( LGX818) plus binimetinib ( MEK162) met the primary endpoint in the first part of the Phase III COLUMBUS study to treat BRAF-mutant melanoma. Patients receiving the combination had significantly longer median progression-free survival (PFS) than those receiving BRAF inhibitor Zelboraf (14.9 vs. 7.3 months, HR=0.54, 95% CI: 0.41, -0.71, p<0.001).

In COLUMBUS's first part, 577 patients received 450 mg encorafenib plus 45 mg binimetinib, 300 mg encorafenib alone, or Zelboraf alone. The combination narrowly missed a secondary endpoint of significantly improving median PFS vs. encorafenib alone (14.9 vs. 9.6 months, p=0.051). ...